Medicine and Health

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation

L. J. Saade and A. Tfayli

This study reveals a significant risk of pneumonitis in stage III NSCLC patients receiving Atezolizumab following chemoradiation, with 8 out of 14 patients affected. Conducted by Lili Jose Saade and Arafat Tfayli, the findings raise concerns about treatment implications and the need for larger studies.

00:00

Playback language: English

Index

Abstract

This study investigated the incidence and severity of pneumonitis in stage III NSCLC patients receiving Atezolizumab as consolidation therapy after concurrent chemoradiation. Of 14 patients, 8 developed pneumonitis. Age, gender, and smoking status did not significantly affect pneumonitis risk. Histology may be a factor, with a higher incidence in squamous cell carcinoma, although this was not statistically significant due to the small sample size. The study highlights the significant risk of pneumonitis with Atezolizumab post chemoradiation and calls for larger studies.

Publisher

Asian Pacific Journal of Cancer Prevention

Published On

Mar 12, 2023

Authors

Lili Jose Saade, Arafat Tfayli

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Lymph Node Ratio Enhances Predictive Value for Treatment Outcomes in Patients with Non-Small Cell Lung Cancer Undergoing Surgery: A Retrospective Cohort Study

S. Wang, N. Mao, et al.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

M. Schuler, K. Cuppens, et al.

Medicine and Health

Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer

Y. Zeng, C. Hu, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny